United States Representative Laurel Lee has disclosed a rare stock purchase in TuHURA Biosciences (NASDAQ: HURA).
Filings show that on July 13, 2025, Lee acquired between $50,001 and $100,000 worth of HURA shares, a small-cap biotech company.
What makes the transaction notable is its uniqueness, where Lee is the only member of Congress known to have ever traded TuHURA Biosciences stock.
Since her purchase, HURA shares have surged 27.04%, far outpacing the S&P 500’s 1.94% gain over the same period.
The trade, disclosed on August 9, 2025, is likely to draw scrutiny over the possible use of insider information, given its timing and outsized returns. Although at the moment, there is no evidence of wrongdoing in the Congress trade.
Receive Signals on US Congress Members' Stock Trades
Stay up-to-date on the trading activity of US Congress members. The signal triggers based on updates from the House disclosure reports, notifying you of their latest stock transactions.
As of press time, HURA stock was trading at $3.08, up over 33% on the day. Year-to-date, however, the stock remains down 23%.
HURA stock fundamentals
At the moment, no immediate catalyst explains HURA’s recent spike, though the company has several supportive fundamentals.
In July, H.C. Wainwright reiterated its ‘Buy’ rating and $12 price target for TuHURA following the launch of a Phase 3 accelerated approval trial for its lead innate immune agonist, IFx-2.0.
The study will test IFx-2.0 as an adjunctive therapy administered weekly for three weeks alongside Merck’s Keytruda, compared to Keytruda plus placebo, in the first-line treatment of advanced or metastatic Merkel cell carcinoma (MCC).
In late June, TuHURA also completed its acquisition of Kineta, adding a Phase 2-ready VISTA-inhibiting monoclonal antibody, now renamed TBS-2025, to its immuno-oncology pipeline. The candidate targets the VISTA immune checkpoint, highly expressed on myeloid cells in the tumor microenvironment.
Featured image via Shutterstock
